---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Natural history, survival, and mortality"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Natural history, survival, and mortality. Topics: Disease course: progressive, monophasic, or relapsing-remitting; Remission and long-term treatment dependence; Mortality: pooled case fatality rate across long-term outcome studies; Mortality compared with the general population: Iceland; 2 further topics. 6 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Disease course: progressive, monophasic, or relapsing-remitting

> “The clinical course was progressive in 6, monophasic in 7, and relapsing–remitting in 10.”

Source: [Laughlin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2707109/)

> “The disease course was remitting-relapsing in 21% and chronic progressive or monophasic in 79%.”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

> “Among patients with CIDP, 78% had a progressive/relapsing course, 14% did not respond to first-line treatments, and 18% could not walk independently at the last visit.”

Source: [Aotsuka et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38408295/)

<a id="topic-2.2.1.3-2"></a>

### Remission and long-term treatment dependence

> “The pooled rate of remission was 40.8% (95% CI, 30.6% to 51.8%).”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

> “The 51 participating patients had a median disease duration of 16 (interquartile range, 14-21) years. Twenty-seven patients (53%) had discontinued therapy and 46 walked independently.”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

> “Approximately 30% of patients can achieve a durable period of drug‐free remission at some point in their disease.”

Source: [Cook et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10098814/)

> “The clinical response to these treatments is usually only partial and transient.”

Source: [Broers et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6518865/)

<a id="topic-2.2.1.3-3"></a>

### Mortality: pooled case fatality rate across long-term outcome studies

> “The pooled case fatality rate was 3.3% (95% confidence interval [CI], 1.9% to 5.7%).”

Source: [Al-Zuhairy and Jakobsen (2023)](https://pubmed.ncbi.nlm.nih.gov/36928889/)

<a id="topic-2.2.1.3-4"></a>

### Mortality compared with the general population: Iceland

> “The standardized mortality ratio for the 21-year study period was 0.9 (95% CI 0.3-2.2).”
> “Many had no or only limited disease progression over the years and mortality is not increased compared with the general population.”

Source: [Hafsteinsdottir and Olafsson (2016)](https://pubmed.ncbi.nlm.nih.gov/27211228/)

<a id="topic-2.2.1.3-5"></a>

### Mortality in treated patients: Denmark

> “For a few patients long-term CIDP was associated with severe morbidity (6%) and even mortality (1%).”

Source: [Al-Zuhairy et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31793666/)

<a id="topic-2.2.1.3-6"></a>

### In-hospital mortality and its predictors: South Korea

> “Furthermore, 129 (13.50%) patients were treated in an ICU, and 80 (8.40%) died while receiving treatment at a medical institution.”
> “Age and the Elixhauser Comorbidity Index were associated with the in-hospital mortality of patients with CIDP. Infection and cardiovascular disease (CVD) were also significantly associated with the in-hospital mortality of those patients.”

Source: [Jung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10622719/)

<a id="topic-2.2.1.3-7"></a>

### Mortality in the United States

No evidence found.

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
